查詢結果分析
來源資料
相關文獻
- Successful Treatment of Transarterial Chemoembolization Combined with Stereotactic Ablative Radiotherapy for Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report
- 肝癌之非外科治療
- 一位行經導管動脈栓塞術肝癌患者之護理經驗
- Percutaneous Drainage of an Infected Biloma Secondary to Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Report of Two Cases
- Preoperative Chemoembolization for the Treatment of Hepatocellular Carcinomas Demonstrating Complicated Anatomical Relationships
- 肝癌經導管動脈化學栓塞術之護理
- 肝臟移植的現況與未來的發展
- 肝臟移植
- 照顧一位肝癌患者接受動脈化學栓塞術後不良反應之護理經驗
- 肝臟移植之病例用藥探討
頁籤選單縮合
題名 | Successful Treatment of Transarterial Chemoembolization Combined with Stereotactic Ablative Radiotherapy for Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report=併用經導管動脈化學栓塞及立體定位消融放射治療成功治療肝癌病人移植後復發:個案報告 |
---|---|
作者 | 羅承翔; 黃文彥; 趙興隆; 林昆澤; 陳昌明; 楊仁富; 張智凱; 林群書; | 書刊名 | 放射治療與腫瘤學 |
卷期 | 24:2 2017.06[民106.06] |
頁次 | 頁161-166 |
分類號 | 416.246 |
關鍵詞 | 肝癌; 肝臟移植; 經導管動脈化學栓塞; 立體定位消融放射治療; 身體立體定位放射治療; Hepatocellular carcinoma; Liver transplantation; Transarterial chemoembolization; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; |
語文 | 英文(English) |
中文摘要 | 我們報告一個罕見肝臟移植後再復發之肝癌個案:一名69歲原發肝癌男性因栓塞效果不佳,在不符合米蘭規約(Milan criteria)條件下接受原位肝臟移植。移植後16個月之電腦斷層影像顯示肝臟植體出現兩處復發病灶,病人因此接受經導管動脈化學栓塞及立體定位消融放射治療之合併療法。病人對此治療方式耐受良好,在治療結束後追蹤的28個月中並無出現任何急性或慢性之副作用。後續追蹤的影像檢查顯示治療部位完全緩解且無復發跡象。此個案報告顯示,在肝臟移植後於肝植體復發之病人,併用經導管動脈化學栓塞及立體定位消融放射治療,可能改善局部腫瘤控制及病人存活。 |
英文摘要 | We describe a rare case of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT). A 69-year-old male underwent orthotopic LT for primary HCC outside of Milan criteria due to incomplete embolization. Sixteen months after LT, contrast-enhanced computed tomography (CT) showed two recurrent tumors in the liver graft. The patient underwent combined TACE and stereotactic ablative radiotherapy (SABR) to treat the recurrent lesions. Twenty-eight months after completion of combined treatment, the patient is doing well without experiencing any acute or chronic adverse effect. Surveillance images demonstrated complete regression and no evidence of recurrence. This case suggests that this dual-modality treatment in the post-transplant setting may help to improve local control and potentially survival in those recipients who develop recurrent HCC within the liver graft. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。